Aelis Farma, a French biopharmaceutical company, announced today that its investigational drug for Down syndrome, AEF0217, has successfully completed an independent safety review. This crucial assessment, conducted by the Data and Safety Monitoring Board (DSMB) for the company's ongoing Phase 2a clinical trial, found no safety concerns, allowing the study to continue as planned.
The Phase 2a trial, known as 'PROOF-DS', commenced in late 2025 and is designed to evaluate the safety, tolerability, and pharmacokinetics of AEF0217 in adults with Down syndrome. The drug is administered twice daily over a three-month period. The positive outcome of this initial safety review is a significant step forward, indicating that the drug has been well-tolerated by participants in the early stages of the study.
AEF0217 operates by targeting the CB1 receptor in the brain, which is implicated in cognitive functions. Pre-clinical studies have suggested that modulating this receptor could help to normalise certain brain activities associated with Down syndrome, potentially leading to improvements in learning and memory. The PROOF-DS trial is therefore not only assessing safety but also exploring early indicators of efficacy.
Currently, the trial is recruiting participants across several clinical centres in Spain and France. The completion of this safety review enables the trial to progress through its various stages, with a focus on gathering comprehensive data on the drug's profile in this patient population. Initial results from the PROOF-DS study are expected to be available sometime in 2027.
This development is particularly notable as there are currently limited pharmacological treatments specifically approved to address the cognitive deficits associated with Down syndrome. Aelis Farma's approach represents a novel therapeutic strategy, and the successful navigation of this safety milestone brings the scientific community closer to understanding the potential of AEF0217.